Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)

NCT05341115 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05341115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05341115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Completed
Start date
March 12, 2023
Completion date
March 10, 2025
Enrollment
79 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

central precocious puberty